Michael Streit, MD serves as Senior Director and Clinical Research Leader in the Oncology Translational Medicine and Early Development Department at Janssen. He is responsible for the clinical development of a novel agonistic anti-CD40 antibody and involved in the management of an emerging portfolio of innovative immuno-therapeutic agents. Dr. Streit trained in Hematology and Medical Oncology at the Free University of Berlin (Germany) and spent 3 years as Research Instructor at the Massachusetts General Hospital (Harvard Medical School). Prior to joining Janssen, Dr. Streit held positions of increasing responsibility in discovery research at Berlex Biosciences and clinical development at Boehringer-Ingelheim, Bristol-Myers-Squibb, and Glaxo-Smith-Kline.
Mark Your Calendars Now!
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October